Wyeth filed a New Drug Application June 23, 2006, with the FDA for Pristiq for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. If approved, Wyeth anticipates that Pristiq will be the first and only non-hormonal medication indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause in the United States. Based on review of publicly disclosed studies, Pristiq is the first non-hormonal therapy to be studied in long-term (six and 12 months), placebo-controlled trials. Pristiq is also under review for the treatment of major depressive disorder, and Wyeth received an approvable letter from the FDA on January 23, 2007, for this indication.
About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical
facts are forward-looking statements based on current expectations
of future events and are subject to risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied by such statements. In particular, the
statements in this press release regarding clinical data and/o